Abstract:The application of population approaches to drug development is recommended in several US Food and Drug Administration (Fl)A) guidance documents. Population pharmacokinetic (and pharmacodynamic) techniques enable identification of the sources of inter- and intra-individual variability that impinge. upon drug Safety and efficacy. This article briefly discusses the 2-stage approach to the estimation of population pharmacokinetic parameters, which requires serial multiple measurements on each participant, and comprehensively reviews the nonlinear mixed-effects. modelling approach, which can be applied in situations where extensive sampling is not done on all or any of the participants.Certain preliminary information, such as the compartment model used in describing the pharmacokinetics of the drug, is required for a population pharmacokinetic study. The practical design considerations of the location of sampling times, number of samples/participants and the need to sample an individual more than once should be borne in mind. Simulation may be useful for choosing the study design that will best meet study objectives.The objectives of the population pharmacokinetic study can be secondary to the objectives of the primary clinical study lin which case an add-on population pharmacokinetic protocol may be needed) or primary (when a stand-alone protocol is required). Having protocols for population pharmacokinetic studies is an integral part of 'good pharmacometric practice'.Real-time data assembly and analysis permit an ongoing evaluation of site compliance with the study protocol and provide the opportunity to correct violations of study procedures. Adequate policies and procedures should be in place for study blind maintenance. Real-time data assembly creates the opportunity for detecting and correcting errors in concentration-time data, drug administration history and covariate data.Population pharmacokinetic analyses may be undertaken in 3 interwoven steps: exploratory data analysis, model development and model validation (i.e. predictive performance). Documentation for regulatory purposes should include a complete inventory of key runs in the analyses undertaken (with flow diagrams if possible), accompanied by articulation of objectives, assumptions and hypotheses. Use of diagnostic analyses of goodness of fit as evidence of reliability of results is advised. Finally, the use of stability testing or model validation may be warranted to support label claims.The opinions expressed in this article were revised by incorporating comments from various sources and published by the FDA as 'Guidance for Industry: Population Pharmacokinetics' (see the FDA home page http://www.fda.gov for further information).

Advantage Of A Population Pharmacokinetic Method For Evaluating The Bioequivalence And Accuracy Of Parameter Estimation Of Pidotimod

Bioequivalence evaluation of two formulations of pidotimod using a limited sampling strategy.

Pharmacokinetic characteristics of single-dose pidotimod injection in Chinese healthy volunteers

A Robust LC–MS/MS Method for the Determination of Pidotimod in Different Biological Matrixes and Its Application to in Vivo and in Vitro Pharmacokinetic Studies

A simulation study of sampling time point designing for therapeutic drug monitoring based on a population pharmacokinetic model

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach

Assessment of Bioequivalence of Citalopram in Healthy Chinese Subjects by Population Pharmacokinetic Model

Population Pharmacokinetics - A Regulatory Perspective

[Modeling and Simulation Activities to Design Sampling Scheme for Population Pharmacokinetic Study on Amlodipine].

Pharmacokinetics and bioavailability of pidotimod in Beagle dog after oral solution and different solid preparations

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay.

Random Sparse Sampling Strategy Using Stochastic Simulation and Estimation for a Population Pharmacokinetic Study

Population pharmacokinetics of combined ethinylestradiol/gestodene transdermal contraceptive tablets and patches in Chinese healthy volunteers

Pharmacokinetics and Relative Bioavailability of a Generic Amisulpride Tablet in Healthy Chinese Volunteers

A UPLC-MS/MS method for quantification of perindopril and perindoprilat and applied in a bioequivalence study for their pharmacokinetic parameter measurement

Study Design and Implementation for Population Pharmacokinetics of Chinese Medicine: an Expert Consensus

Development and Validation of a RP-HPLC Method for Determination of Pidotimod in Plasma and its Efficient Application to a Pharmacokinetic Study

Pharmacokinetics and Bioequivalence Assessment of Phenoxymethylpenicillin Potassium Tablets in Chinese Healthy Volunteers

Adaptive seamless design for establishing pharmacokinetics and efficacy equivalence in developing biosimilars

Systematic Evaluation of Dose Proportionality Studies in Clinical Pharmacokinetics.